scholarly journals Oxidant-antioxidant status in colorectal cancer patients—Before and after treatment

2004 ◽  
Vol 19 (2) ◽  
pp. 80-83 ◽  
Author(s):  
Sharmila Upadhya ◽  
Subramanya Upadhya ◽  
S. Krishna Mohan ◽  
K. Vanajakshamma ◽  
Mamatha Kunder ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Antioxidant Status ◽  
Before And After ◽  
Colorectal Cancer Patients

Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients

2002 ◽  
Vol 17 (1) ◽  
pp. 63-66 ◽  
Author(s):  
R.A. Merendino ◽  
A. Ruello ◽  
S. Cascinu ◽  
B. Ferlazzo ◽  
A. Bene ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Folinic Acid ◽  
Cancer Patients ◽  
Serum Levels ◽  
Interleukin 18 ◽  
Blood Concentrations ◽  
Healthy Donors ◽  
Before And After ◽  
Colorectal Cancer Patients

Aims and Background This study was carried out to evaluate the IL-18 blood concentrations of operated colorectal cancer patients and their possible variation in response to combination chemotherapy with 5-fluorouracil (5-FU) and folinic acid. Methods IL-18 levels were assayed in sera of 18 healthy donors and 18 surgical colorectal cancer patients before and after adjuvant chemotherapy with 5-fluorouracil and folinic acid. An ELISA kit for human IL-18 was used for the assay. Results Colorectal cancer patients showed significantly higher baseline levels of IL-18 than healthy donors (p<0.005). Furthermore, serum IL-18 levels increased significantly with respect to baseline in patients receiving adjuvant chemotherapy (p<0.005). Conclusions This study suggests that treatment with 5-fluorouracil and folinic acid may provoke an increase in IL-18 serum levels in colorectal cancer patients. This increase may help to explain the efficacy of adjuvant chemotherapy with 5-FU in colorectal cancer.

CTLs/regulatory T-cells ratio as a prediction marker of chemotherapy in metastatic colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14684-e14684
Author(s):  
Teruo Sasatomi ◽  
Takafumi Oochi ◽  
Yutaka Ogata ◽  
Yoshito Akagi ◽  
Kazuo Shirouzu
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Metastatic Lesion ◽  
The Other ◽  
Before And After ◽  
Colorectal Cancer Patients

e14684 Background: Many multiple anti cancer drugs regimens have been established for metastaticcolorectal cancer recently. We investigated cellular immunoreaction of these patients to their cancer. Methods: 32 metastatic colorectal cancer patients have been started chemotherapies. Their PBMCs were harvested and investigated their character by Fac scan with fluorescent labeled antibodies (CD3,CD8, CD4, CD25, Foxp3) at before and after chemotherapy. Results: After chemotherapy, both CTLs(CD3, CD8 positive) and regulatory T cells (CD4, CD25, Foxp3 positive) were decreased in number among all patients. On the other hand, CTL/T reg ratio were significantly increased among tumor marker decreased patients and significantly decreased among tumor marker increased or stable patients. CEA levels among 85.7% of increased CTL/T reg ratio patients became to decrease less thanhalf. CEA levels among 66.7% of decreased CTL/T reg ratio patients became to increase or to be stable, if their regimens have not been changed. The Reactive Rate of chemotherapy of CTL/T reg ratio increased patients was significantly higher than that of ratio decreased or stable patients. (P=0.021) The Disease Control Rate of chemotherapy of CTL/T reg ratio increased patients was higher than that of ratio decreased patients. Both resectability rate of liver metastatic lesion and early tumor shrinkage rate were higher at the CTL/T reg ratio increased patients group than at the other patients group. Conclusions: We found that the CTL/T reg ratios of PBMC in metastatic colorectal cancer patients were useful for prediction of the effect of chemotherapy.

scholarly journals Metabolic Profiling of Urine Samples from Colorectal Cancer Patients Before and After Surgical Treatments

2010 ◽  
Vol 14 (1) ◽  
pp. 28-37 ◽  
Author(s):  
Young-Kee Chae ◽  
Woo-Young Kang ◽  
Seong-Hwan Kim ◽  
Jong-Eun Joo ◽  
Joon-Kil Han ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Metabolic Profiling ◽  
Urine Samples ◽  
Before And After ◽  
Colorectal Cancer Patients ◽  
Surgical Treatments

Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery

2019 ◽  
Vol 65 (6) ◽  
pp. 44 ◽  
Author(s):  
Guangxin Cao ◽  
Yu Xie ◽  
Xiaohui Jiang ◽  
Xiaofeng Tian ◽  
Ding Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Cell Free Dna ◽  
Free Dna ◽  
Before And After ◽  
Colorectal Cancer Patients ◽  
Integrity Analysis

scholarly journals Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients

2019 ◽  
Vol 65 (2) ◽  
pp. 177-182
Author(s):  
Kong Ying ◽  
Yang Chong ◽  
Wang Wei ◽  
Dong Bing ◽  
Su Yanyan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Total Efficiency ◽  
Therapeutic Effects ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Before And After ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

SUMMARY OBJECTIVE: To explore the effect of FOLFOX6 chemotherapy on serum vascular endothelial growth factor (VEGF) expression in advanced colorectal cancer patients. METHODS: A retrospective analysis of 81 patients with advanced colorectal cancer who visited our hospital from March 2014 to February 2016 was performed. All the patients were treated with FOLFOX6 chemotherapy. On day 1, patients received oxaliplatin 100 mg/m2 ivgtt (2h), calcium folinate 200 mg/m2 ivgtt (2h), 5 fluorouracil 400 mg/m2 iv bolus and 5 fluorouracil 2500 mg/m2 ivgtt (5h). The treatment course was 2 weeks, and 4 treatment courses were required. The changes in the levels of VEGF and CRP and quality of life before and after 4 courses of chemotherapy were observed and therapeutic effects and adverse reactions after chemotherapy were evaluated. RESULTS: After treatment, the total efficiency of chemotherapy was 82.72% (67/81) with 24 cases in complete remission, 25 cases in partial response, 18 cases in stable disease and 14 cases in progressive disease. The levels of CRP and VEGF after the treatment were significantly lower than those before treatment (5.69±0.77) mg/L vs. (7.99±1.36) mg/L; (443.26±21.55) pg/mL vs. (542.83±20.44) pg/mL] (P<0.05). The KPS grade after treatment was significantly higher than that before treatment (57.84±4.6) point vs. (50.99±3.73) point] (P<0.05). Among them, 3 cases developed a rash, 5 cases experienced hair loss, and 9 cases developed nausea and vomiting. CONCLUSION: FOLFOX6 chemotherapy can decrease serum VEGF expression in patients with advanced colorectal cancer and enhance the curative effect with high safety, which is good for the improvement of patients' survival.

scholarly journals Serum ROBO4 and CLEC14A: Preliminary Evaluation as Diagnostic and Progression Biomarkers in Colorectal Cancer Patients

2021 ◽  
Author(s):  
Łukasz Pietrzyk ◽  
Kamil Torres
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Distant Metastases ◽  
Tnm Stage ◽  
Preliminary Evaluation ◽  
Depth Of Invasion ◽  
Clinical Value ◽  
Before And After ◽  
Preliminary Study ◽  
Colorectal Cancer Patients

Abstract Colorectal cancer (CRC) is an important global burden, and the discovery of biomarkers for screening and monitoring is a current challenge. The present study aimed to determine the serum concentration of ROBO4 and CLEC14A in CRC patients and assess the clinical value of these diagnostic and progression biomarkers in CRC. The ROBO4 and CLEC14A levels were measured using ELISA tests. Blood sera were tested in 32 CRC patients and 16 controls at two time points (before and after surgery). The serum concentrations of ROBO4 and CLEC14A were significantly higher in CRC patients than non-cancer controls; the concentrations were already higher in TNM stage I+II CRC patients. The sensitivitiy and specificity of ROBO4 and CLEC14A in distiguishing cancer patients form controls ranged from 71.9% to 100% and from 84.5% to 100%, respectively. The serum ROBO4 concentration was associated with the TNM stage, depth of invasion, and lymph node and distant metastases. No significant relationship was observed between the CLEC14A concentration and the tumor site or the N and M stages. The level of ROBO4 was statistically lower 3 months after the surgery, compared to the level noted prior to the operation. The concentration of CLEC14A decreased in the postoperative period, compared to preoperative one; however, the decline was not statistically significant. Our preliminary study has provided evidence that ROOB4 and CLEC14A seem to be suitable biomarkers for clinical diagnostic purposes. However, ROOB4 appears to be more appropriate for assessment of CRC progression.

Immunological effects as a biomarker of chemotherapy in metastatic colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14077-e14077
Author(s):  
Teruo Sasatomi ◽  
Yutaka Ogata ◽  
Hideaki Yamana ◽  
Yoshito Akagi ◽  
Kazuo Shirouzu
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
The Other ◽  
Anti Cancer ◽  
Before And After ◽  
Immunological Effects ◽  
Colorectal Cancer Patients

e14077 Background: Many multiple anti cancer drugs regimens have been established for metastatic colorectal cancer recently. We investigated cellular immunoreaction of these patients to their cancer. Methods: 26 metastatic colorectal cancer patients have been started chemotherapies. Their PBMC were harvested and investigated their character by Fac scan with fluorescent labeled antibodies (CD3, CD8, CD4, CD25, Foxp3) at before and after chemotherapy. Results: After chemotherapy, both CTLs (CD3, CD8 positive) and regulatory T cells (CD4, CD25, Foxp3 positive) were decreased in number among all patients. On the other hand, CTL/T reg ratio were significantly increased among tumor marker decreased patients and significantly decreased among tumor marker increased or stable patients. CEA levels among 85.7% of increased CTL/T reg ratio patients became to decrease less than half. CEA levels among 66.7% of decreased CTL/T reg ratio patients became to increase or to be stable, if their regimens have not been changed. The Reactive Rate of chemotherapy of CTL/T reg ratio increased patients was significantly higher than that of ratio decreased patients. (p=0.021) The Disease Control Rate of chemotherapy of CTL/T reg ratio increased patients was higher than that of ratio decreased patients. Conclusions: We found that the CTL/T reg ratio of PBMC in metastatic colorectal cancer patients were useful for prediction of the effect of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document